Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Part 1 and 2 Clear all
Completed Phase 2 Interventional Results available

Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

NCT02659059
View directory record Official record
Conditions
Non-Small-Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Platinum Doublet Chemotherapy
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
29
States / cities
San Diego, California • Plainville, Connecticut • Weston, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Xanomeline With Trospium Chloride Versus KarXT in Healthy Adult and Elderly Participants of Japanese Ethnicity and to Assess the Effect of Omeprazole on the PK of Xanomeline With Trospium Chloride in Healthy Adult Participants

NCT06605950
View directory record Official record
Conditions
Healthy Volunteers
Interventions
KarXT, KarX-EC, Placebo, Omeprazole
Drug
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Industry
Eligibility
19 Years to 90 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 2 Interventional

A Clinical Trial in Subjects With Atopic Dermatitis (Part 1)

NCT05717920
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ADX-629 (Open-label)
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bexley, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, and Pharmacokinetic Study of NIP292 in Healthy Normal Subjects

NCT04720443
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
NIP292 tablet, NIP292 tablets
Drug
Lead sponsor
The National Institutes of Pharmaceutical R&D Co. Ltd, China
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Jul 22, 2026, 2:10 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B

NCT06680232
View directory record Official record
Conditions
HEPATITIS B CHRONIC
Interventions
PBGENE-HBV
Biological
Lead sponsor
Precision BioSciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Jul 22, 2026, 2:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Modular Phase 1/2 Study With CT7439 in Participants With Solid Malignancies

NCT06600789
View directory record Official record
Conditions
Solid Malignancies
Interventions
CT7439 Capsules (0.5 mg, 1mg, 3mg)
Drug
Lead sponsor
Carrick Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Dallas, Texas • San Antonio, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS

NCT05093205
View directory record Official record
Conditions
Healthy Adults
Interventions
PF-06882961, Atorvastatin, Midazolam, Levonorgestrel & Ethinyl Estradiol
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Jul 22, 2026, 2:10 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Effects of Age and Exercise on Blood Pressure Regulation

NCT00319397
View directory record Official record
Conditions
Cardiovascular Disease, Aging
Interventions
Exercise-Training Program
Behavioral
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 13, 2009 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Single Ascending Dose and Multiple Ascending Doses of Oral AFA-281 in Healthy Volunteers

NCT05547503
View directory record Official record
Conditions
Pain, Neuropathic, Pain, Inflammatory
Interventions
AFA-281
Drug
Lead sponsor
Afasci Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer

NCT00460603
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
bevacizumab, AG-013726, AG-013736 (axitinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
106
States / cities
Daphne, Alabama • Huntsville, Alabama • Mobile, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Jul 22, 2026, 2:10 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

NCT03866577
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura (ITP)
Interventions
Biological: M254, Placebo, Intravenous immunoglobulin (IVIg)
Biological · Drug
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Whittier, California • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults

NCT04580654
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CSL312
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn if the Study Medicine Called Itraconazole and if Food Changes How the Body Processes the Other Study Medicine Called PF 07258669 in Older Adults or Healthy Adults

NCT06706869
View directory record Official record
Conditions
Healthy
Interventions
PF-07258669, Itraconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Jul 22, 2026, 2:10 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)

NCT06782373
View directory record Official record
Conditions
VEXAS, VEXAS Syndrome
Interventions
Pacritinib, Placebo
Drug
Lead sponsor
Swedish Orphan Biovitrum
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

NCT06593457
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IP, Matching Placebo
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Jul 22, 2026, 2:10 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

NCT06597019
View directory record Official record
Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
Inclisiran, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 11 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 22, 2026, 2:10 AM EDT
Terminated Phase 1 Interventional

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

NCT06406400
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
AZD4041, Itraconazole, Buprenorphine, Buprenorphine / Naloxone, Hydromorphone, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Jul 22, 2026, 2:10 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants

NCT07226817
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986435
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 22, 2026, 2:10 AM EDT
Recruiting Phase 1Phase 2 Interventional

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

NCT07262619
View directory record Official record
Conditions
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions
EIK1005, pembrolizumab (KEYTRUDA® )
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Morristown, New Jersey • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral ARN-75039 in Healthy Adult Subjects

NCT05735249
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
ARN-75039 oral capsules, Placebo
Drug
Lead sponsor
Arisan Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566

NCT05844735
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAR441566, Placebo, Ciprofloxacin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 22, 2026, 2:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)

NCT02653391
View directory record Official record
Conditions
Fuchs' Corneal Endothelial Dystrophy (FCED)
Interventions
Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution, Part A Placebo, Part B Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Edgewood, Kentucky • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Jul 22, 2026, 2:10 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

NCT06139055
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet)
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Jul 22, 2026, 2:10 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

NCT05629741
View directory record Official record
Conditions
Community-acquired Pneumonia, Bacterial Pneumonia
Interventions
CMTX-101, Placebo
Drug
Lead sponsor
Clarametyx Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
8
States / cities
Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jul 22, 2026, 2:10 AM EDT